Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo para avaliar os eventos adversos, a eficácia e a dose ideal de telisotuzumabe adizutecano intravenoso (IV) em combinação com budigalimabe intravenoso em participantes adultos com NSCLC não escamoso avançado ou metastático, sem tratamento prévio para doença avançada e sem alterações genômicas acionáveis

17 de novembro de 2026 atualizado por: AbbVie

Um estudo aberto de multicoorte de fase 1b/2 para avaliar a segurança, eficácia e dose ideal de telisotuzumabe adizutecano em combinação com budigalimabe em NSCLC não escamoso avançado ou metastático, sem tratamento prévio para doença avançada e sem alterações genômicas acionáveis

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC.

Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide.

In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

252

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Alemanha, 79106
        • Recrutamento
        • Universitaetsklinikum Freiburg /ID# 268473
      • Heilbronn, Baden-Wurttemberg, Alemanha, 74078
        • Recrutamento
        • Slk-Kliniken Heilbronn /ID# 269621
    • Bavaria
      • Augsburg, Bavaria, Alemanha, 86150
        • Recrutamento
        • Hamatologie-Onkologie im Zentrum MVZ GmbH /ID# 273043
      • Würzburg, Bavaria, Alemanha, 97080
        • Recrutamento
        • Universitaetsklinikum Wuerzburg /ID# 275445
    • Hesse
      • Frankfurt am Main, Hesse, Alemanha, 60590
        • Recrutamento
        • Universitaetsklinikum Frankfurt /ID# 268721
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Alemanha, 50937
        • Recrutamento
        • Universitaetsklinikum Koeln /ID# 268489
      • Hemer, North Rhine-Westphalia, Alemanha, 58675
        • Recrutamento
        • Lungenklinik Hemer /ID# 269779
    • Schleswig-Holstein
      • Oldenburg in Holstein, Schleswig-Holstein, Alemanha, 23758
        • Recrutamento
        • ohO Research GmbH /ID# 273060
    • Thuringia
      • Jena, Thuringia, Alemanha, 07747
        • Recrutamento
        • Universitatsklinikum Jena /ID# 269700
      • Buenos Aires, Argentina, 1426
        • Recrutamento
        • Centro Oncologico Korben /ID# 281460
      • Buenos Aires, Argentina, 1426
        • Recrutamento
        • Fundacion Respirar /ID# 281039
    • Buenos Aires
      • Mar del Plata, Buenos Aires, Argentina, 7600
        • Recrutamento
        • Clinca Colon /ID# 281465
    • Buenos Aires F.D.
      • Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina, 1426
        • Recrutamento
        • Instituto Alexander Fleming /ID# 282704
    • New South Wales
      • Blacktown, New South Wales, Austrália, 2148
        • Recrutamento
        • Blacktown Hospital /ID# 281588
    • Queensland
      • Townsville, Queensland, Austrália, 4814
        • Recrutamento
        • Townsville University Hospital /ID# 281498
    • South Australia
      • Elizabeth Vale, South Australia, Austrália, 5112
        • Recrutamento
        • Lyell Mcewin Hospital /ID# 281860
    • Victoria
      • Frankston, Victoria, Austrália, 3199
        • Recrutamento
        • Peninsula University Hospital /ID# 281824
      • Liège, Bélgica, 4000
        • Recrutamento
        • Groupe Sante CHC - Clinique du MontLegia /ID# 271760
    • Limburg
      • Hasselt, Limburg, Bélgica, 3500
        • Recrutamento
        • Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573
    • Oost-Vlaanderen
      • Sint-Niklaas, Oost-Vlaanderen, Bélgica, 9100
        • Recrutamento
        • Vitaz /Id# 280187
    • West-Vlaanderen
      • Roeselare, West-Vlaanderen, Bélgica, 8800
        • Recrutamento
        • AZ-Delta. /ID# 272433
    • Region Metropolitana Santiago
      • Santiago, Region Metropolitana Santiago, Chile, 8330032
        • Recrutamento
        • Pontificia Universidad Catolica De Chile /ID# 281594
      • Vitacura, Region Metropolitana Santiago, Chile, 7650027
        • Recrutamento
        • Oncored /Id# 281108
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 6900941
        • Recrutamento
        • Fundacion Arturo Lopez Perez /ID# 281211
      • Santiago, Santiago Metropolitan, Chile, 7500713
        • Recrutamento
        • Orlandi Oncologia /ID# 281132
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100021
        • Recrutamento
        • Cancer Hospital - Chinese Academy of Medical Sciences /ID# 269715
    • Fujian
      • Fuzhou, Fujian, China, 350014
        • Recrutamento
        • Fujian Province Cancer Hospital /ID# 269150
    • Guangxi
      • Liuzhou, Guangxi, China, 545006
        • Recrutamento
        • Liuzhou People's hospital /ID# 269667
    • Henan
      • Zhengzhou, Henan, China, 450008
        • Recrutamento
        • Henan Cancer Hospital /ID# 269668
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Recrutamento
        • Union Hospital - Tongji Medical College /ID# 272286
    • Hunan
      • Changsha, Hunan, China, 410013
        • Recrutamento
        • Hunan Province Cancer Hospital /ID# 269679
    • Jiangsu
      • Nanjing, Jiangsu, China, 210008
        • Recrutamento
        • Nanjing Drum Tower Hospital /ID# 269762
    • Jiangxi
      • Nanchang, Jiangxi, China, 330209
        • Recrutamento
        • The First Affiliated Hospital of Nanchang University - Xianghu Campus /ID# 269190
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • Recrutamento
        • The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271904
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200030
        • Recrutamento
        • Shanghai Chest Hospital /ID# 269155
      • Shanghai, Shanghai Municipality, China, 200433
        • Recrutamento
        • Shanghai Pulmonary Hospital /ID# 276397
    • Shanxi
      • Taiyuan, Shanxi, China, 030001
        • Recrutamento
        • First Affiliated Hospital of Shanxi Medical University /ID# 276482
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Recrutamento
        • West China Hospital of Sichuan University /ID# 270244
      • Chengdu, Sichuan, China, 610041
        • Recrutamento
        • Sichuan Province Cancer Hospital /ID# 269712
    • Yunnan
      • Kunming, Yunnan, China, 650106
        • Recrutamento
        • Yunnan Province Cancer Hospital /ID# 272331
      • A Coruña, Espanha, 15006
        • Recrutamento
        • Complejo Hospitalario Universitario A Coruna /ID# 271456
      • Alicante, Espanha, 03010
        • Recrutamento
        • Hospital General Universitario de Alicante /ID# 271316
      • Barcelona, Espanha, 08036
        • Recrutamento
        • Hospital Clinic de Barcelona /ID# 271452
      • Barcelona, Espanha, 08041
        • Recrutamento
        • Hospital Santa Creu i Sant Pau /ID# 271311
      • Barcelona, Espanha, 08003
        • Recrutamento
        • Hospital del Mar /ID# 271310
      • Málaga, Espanha, 29010
        • Recrutamento
        • Hospital Universitario Virgen de la Victoria /ID# 271312
    • Cantabria
      • Santander, Cantabria, Espanha, 39008
        • Recrutamento
        • Hospital Universitario Marques de Valdecilla /ID# 271314
    • Sevilla
      • Seville, Sevilla, Espanha, 41009
        • Recrutamento
        • Hospital Universitario Virgen Macarena /ID# 271447
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85054
        • Ativo, não recrutando
        • Mayo Clinic Hospital - Phoenix /ID# 272971
    • California
      • Fullerton, California, Estados Unidos, 92835
        • Recrutamento
        • Providence - St. Jude Medical Center /ID# 271414
      • Oxnard, California, Estados Unidos, 93030
        • Recrutamento
        • FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450
      • Santa Monica, California, Estados Unidos, 90404
        • Recrutamento
        • UCLA - Santa Monica /ID# 271690
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Recrutamento
        • University Of Colorado - Anschutz Medical Campus /ID# 269069
      • Lone Tree, Colorado, Estados Unidos, 80124
        • Recrutamento
        • Rocky Mountain Cancer Centers - Lone Tree /ID# 272603
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224
        • Recrutamento
        • Mayo Clinic Hospital Jacksonville /ID# 275073
      • Orange City, Florida, Estados Unidos, 32763
        • Recrutamento
        • Mid Florida Hematology And Oncology Center /ID# 273777
    • Illinois
      • Hinsdale, Illinois, Estados Unidos, 60521
        • Recrutamento
        • Hope And Healing Cancer Services /ID# 276223
        • Contato:
          • Site Coordinator
          • Número de telefone: 6305600121
    • Indiana
      • Fort Wayne, Indiana, Estados Unidos, 46845
        • Recrutamento
        • Parkview Comprehensive Cancer Center /ID# 271879
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Concluído
        • Community Health Network /ID# 273437
    • Kansas
      • Overland Park, Kansas, Estados Unidos, 66210
        • Recrutamento
        • Kansas City Cancer Center /ID# 273679
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Recrutamento
        • Dana-Farber Cancer Institute /ID# 278417
    • Michigan
      • Detroit, Michigan, Estados Unidos, 48202
        • Recrutamento
        • Henry Ford Hospital - Detroit /ID# 271642
    • Minnesota
      • Duluth, Minnesota, Estados Unidos, 55805
        • Recrutamento
        • St. Luke'S /ID# 273344
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic-Rochester /ID# 274512
    • New Jersey
      • East Brunswick, New Jersey, Estados Unidos, 08816-4096
        • Recrutamento
        • Astera Cancer Care /ID# 271915
    • New York
      • Shirley, New York, Estados Unidos, 11967
        • Recrutamento
        • New York Cancer And Blood Specialists - Shirley /ID# 272547
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • Concluído
        • University Hospitals Cleveland Medical Center /ID# 271726
      • Columbus, Ohio, Estados Unidos, 43219
        • Recrutamento
        • The Mark H Zangmeister Center /ID# 272502
    • Pennsylvania
      • Easton, Pennsylvania, Estados Unidos, 18045
        • Recrutamento
        • Spoknwrd Clinical Trials /ID# 273776
        • Contato:
          • Site Coordinator
          • Número de telefone: 610-813-2087
    • Texas
      • Houston, Texas, Estados Unidos, 77090
        • Concluído
        • Millennium Physicians /ID# 271717
      • Lubbock, Texas, Estados Unidos, 79410-1121
        • Recrutamento
        • Joe Arrington Cancer Research /ID# 272776
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Recrutamento
        • Huntsman Cancer Institute /ID# 271686
    • Virginia
      • Leesburg, Virginia, Estados Unidos, 20176
        • Recrutamento
        • Virgnia Cancer Specialists /ID# 269633
    • Washington
      • Olympia, Washington, Estados Unidos, 98506
        • Recrutamento
        • Vista Oncology - East Olympia /ID# 275438
      • Tacoma, Washington, Estados Unidos, 98405
        • Recrutamento
        • Northwest Medical Specialties Tacoma /ID# 270469
    • Gironde
      • Bordeaux, Gironde, França, 33000
        • Recrutamento
        • Institut Bergonie /ID# 258377
    • Loire-Atlantique
      • Saint-Herblain, Loire-Atlantique, França, 44800
        • Recrutamento
        • CHU Nantes - Hopital Laennec /ID# 268475
      • Saint-Herblain, Loire-Atlantique, França, 44805
        • Recrutamento
        • Institut de Cancerologie de l'Ouest Rene Gauducheau /ID# 268484
    • Occitanie
      • Montpellier, Occitanie, França, 34070
        • Recrutamento
        • Centre De Cancerologie Du Grand Montpellier /ID# 273724
    • Provence-Alpes-Côte d'Azur Region
      • Nice, Provence-Alpes-Côte d'Azur Region, França, 06189
        • Recrutamento
        • Centre Antoine-Lacassagne /ID# 268486
    • Val-de-Marne
      • Villejuif, Val-de-Marne, França, 94805
        • Recrutamento
        • Institut Gustave Roussy /ID# 258373
    • Île-de-France Region
      • Paris, Île-de-France Region, França, 75248
        • Recrutamento
        • Institut Curie /ID# 271395
      • Bologna, Itália, 40138
        • Recrutamento
        • IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 268675
    • Forlì-Cesena
      • Meldola, Forlì-Cesena, Itália, 47014
        • Recrutamento
        • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST - IRCCS /ID# 268684
    • Milano
      • Milan, Milano, Itália, 20121
        • Recrutamento
        • Istituto Europeo Di Oncologia /Id# 268670
    • Roma
      • Rome, Roma, Itália, 00144
        • Recrutamento
        • IRCCS Istituti Fisioterapici Ospitalieri-Istituto Nazionale Tumori Regina Elena /ID# 268626
      • Rome, Roma, Itália, 00184
        • Recrutamento
        • Azienda Ospedaliera Complesso Ospedaliero San Giovanni-Addolorata /ID# 273438
    • The Marches
      • Ancona, The Marches, Itália, 60126
        • Recrutamento
        • Azienda Ospedaliero Universitaria delle Marche /ID# 268667
    • Torino
      • Orbassano, Torino, Itália, 10043
        • Recrutamento
        • Azienda Ospedaliero Universitaria San Luigi Gonzaga /ID# 268641
      • Nagasaki, Japão, 852-8501
        • Recrutamento
        • Nagasaki University Hospital /ID# 273310
    • Aichi-ken
      • Nagoya, Aichi-ken, Japão, 460-0001
        • Recrutamento
        • NHO Nagoya Medical Center /ID# 272515
      • Nagoya, Aichi-ken, Japão, 464-8681
        • Recrutamento
        • Aichi Cancer Center /ID# 271978
    • Aomori
      • Hirosaki, Aomori, Japão, 036-8563
        • Recrutamento
        • Hirosaki University Hospital /ID# 274410
    • Kanagawa
      • Yokohama, Kanagawa, Japão, 221-0855
        • Recrutamento
        • Yokohama Municipal Citizen's Hospital /ID# 271979
    • Kyoto
      • Kyoto, Kyoto, Japão, 606-8507
        • Recrutamento
        • Kyoto University Hospital /ID# 272312
    • Niigata
      • Niigata, Niigata, Japão, 951-8520
        • Recrutamento
        • Niigata University Medical and Dental Hospital /ID# 274448
    • Osaka
      • Takatsuki, Osaka, Japão, 569-8686
        • Recrutamento
        • Osaka Medical And Pharmaceutical University Hospital /ID# 273309
    • Tokyo
      • Chuo-Ku, Tokyo, Japão, 104-0045
        • Recrutamento
        • National Cancer Center Hospital /ID# 273192
      • Koto-ku, Tokyo, Japão, 135-8550
        • Recrutamento
        • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 271989
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polônia, 20-090
        • Recrutamento
        • Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie /ID# 273170
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Polônia, 15-540
        • Recrutamento
        • Uniwersytecki Szpital Kliniczny w Bialymstoku /ID# 276848
    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polônia, 80-214
        • Recrutamento
        • Uniwersyteckie Centrum Kliniczne /ID# 272418
    • Świętokrzyskie Voivodeship
      • Kielce, Świętokrzyskie Voivodeship, Polônia, 25-734
        • Recrutamento
        • Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 274549
      • Rio Piedras, Porto Rico, 00935
        • Recrutamento
        • Pan American Center for Oncology Trials - Rio Piedras /ID# 268827
      • Cardiff, Reino Unido, CF14 2TL
        • Recrutamento
        • Velindre Cancer Centre /ID# 271840
    • Leicestershire
      • Leicester, Leicestershire, Reino Unido, LE1 5WW
        • Recrutamento
        • University Hospitals of Leicester NHS Trust /ID# 276035
      • Bucharest, Romênia, 013975
        • Recrutamento
        • MNT Healthcare Europe SRL /ID# 269075
      • Bucharest, Romênia, 030171
        • Recrutamento
        • Spitalul Clinic Coltea /ID# 268726
      • Sibiu, Romênia, 550253
        • Recrutamento
        • Clinica MedLife Polisano Sibiu /ID# 269078
    • Cluj
      • Cluj-Napoca, Cluj, Romênia, 400080
        • Recrutamento
        • S.C. Radiotherapy Center Cluj SRL /ID# 268729
      • Cluj-Napoca, Cluj, Romênia, 400015
        • Recrutamento
        • Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 273125
      • Cluj-Napoca, Cluj, Romênia, 400015
        • Recrutamento
        • Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca /ID# 268725
      • Changhua, Taiwan, 500
        • Recrutamento
        • Changhua Christian Hospital /ID# 280139
      • Chiayi City, Taiwan, 62247
        • Recrutamento
        • Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation /ID# 268789
      • Kaohsiung City, Taiwan, 807
        • Recrutamento
        • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 268139
      • Kaohsiung City, Taiwan, 833
        • Recrutamento
        • Kaohsiung Chang Gung Memorial Hospital /ID# 268138
      • Taipei, Taiwan, 114
        • Recrutamento
        • Tri-Service General Hospital /ID# 269211
      • Taipei, Taiwan, 106
        • Recrutamento
        • National Taiwan University Cancer Center (Ntucc) /ID# 271586
      • Taipei, Taiwan, 112
        • Recrutamento
        • Taipei Veterans General Hospital /ID# 268787
      • Taoyuan City, Taiwan, 333
        • Recrutamento
        • Linkou Chang Gung Memorial Hospital /ID# 268137
      • Adana, Turquia (Türkiye), 01140
        • Recrutamento
        • Adana Medical Park Seyhan Hastanesi /ID# 272875
      • Ankara, Turquia (Türkiye), 06620
        • Recrutamento
        • Ankara Universitesi Tip Fakultesi Cebeci Hastanesi /ID# 272873
      • Ankara, Turquia (Türkiye), 06680
        • Recrutamento
        • Liv Hospital Ankara /ID# 272876
      • Ankara, Turquia (Türkiye), 06230
        • Recrutamento
        • Hacettepe Universitesi Tip Fakultesi /ID# 280631
      • Denizli, Turquia (Türkiye), 20070
        • Recrutamento
        • Pamukkale Universitesi /ID# 272893
      • Istanbul, Turquia (Türkiye), 34722
        • Recrutamento
        • Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi /ID# 280635
      • Konya, Turquia (Türkiye), 42080
        • Recrutamento
        • Necmettin Erbakan Universitesi Meram Tip Fakultesi - Eski Hastane /ID# 272882
      • Samsun, Turquia (Türkiye), 55139
        • Recrutamento
        • Ondokuz Mayis Universitesi /ID# 272899
      • Samsun, Turquia (Türkiye), 55200
        • Recrutamento
        • Samsun Medical Park Hastanesi /ID# 272880
    • Antalya
      • Ankara, Antalya, Turquia (Türkiye), 06010
        • Recrutamento
        • Gulhane Egitim ve Arastirma Hastanesi /ID# 280715
    • Sakarya
      • Adapazarı, Sakarya, Turquia (Türkiye), 54290
        • Recrutamento
        • Sakarya Egitim ve Arastirma Hastanesi /ID# 272878

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study.
  • Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
  • For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC.
  • For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration.
  • Must have documented programmed death ligand 1 (PD-L1) status.
  • For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization.
  • Must have adequate organ function.

Exclusion Criteria:

  • Known uncontrolled metastases to the central nervous system.
  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Part 1: Telisotuzumab Adizutecan + Budigalimab

Participants will receive several doses of telisotuzumab adizutecan in combination with budigalimab, as part of the 33 month study duration.

Intravenous (IV) Infusion

Outros nomes:
  • ABBV-400

IV Infusion

Outros nomes:
  • ABBV-181
Experimental: Part 2 Arm 1: Telisotuzumab Adizutecan + Pembrolizumab

Participants will receive telisotuzumab adizutecan dose A in combination with pembrolizumab, as part of the 33 month study duration.

Intravenous (IV) Infusion

Outros nomes:
  • ABBV-400

IV Injection

IV Infusion

Experimental: Part 2 Arm 2: Telisotuzumab Adizutecan + Pembrolizumab

Participants will receive telisotuzumab adizutecan dose B in combination with pembrolizumab, as part of the 33 month study duration.

Intravenous (IV) Infusion

Outros nomes:
  • ABBV-400

IV Injection

IV Infusion

Experimental: Part 2: Standard of Care

Participants will receive pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed, as part of the 33 month study duration.

IV Infusion

IV Infusion

IV Injection

IV Infusion

IV Infusion

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
Prazo: Up to Approximately 84 Days

DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.

Up to Approximately 84 Days
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Prazo: Up to Approximately 33 Months

OR is defined as confirmed complete response (CR) or confirmed partial response (PR) per BICR based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Up to Approximately 33 Months
Number of Participants with Adverse Events (AE)s
Prazo: Up to Approximately 33 Months

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Up to Approximately 33 Months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Part 1 and Part 2: PFS as Assessed by Investigator
Prazo: Up to Approximately 33 Months

PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression per Investigator based on RECIST v1.1 or death from any cause, whichever occurs earlier.

Up to Approximately 33 Months
Part 1 and Part 2: DOR as Assessed by Investigator
Prazo: Up to Approximately 33 Months

DOR is defined as the time from the first documented CR or PR per investigator to the first occurrence of radiographic progression per the investigator on RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR.

Up to Approximately 33 Months
Part 1 and Part 2: DC as Assessed by Investigator
Prazo: Up to Approximately 33 Months

DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 11 weeks following randomization date based on RECIST v1.1, as determined by the Investigator.

Up to Approximately 33 Months
Part 1 and Part 2: Overall Survival (OS)
Prazo: Up to Approximately 33 Months

OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause.

Up to Approximately 33 Months
Programmed Death Ligand 1 (PD-L1) and c-Met Subgroups: OR
Prazo: Up to Approximately 33 Months

OR is defined as confirmed CR or confirmed PR based on RECIST v1.1.

Up to Approximately 33 Months
PD-L1 and c-Met Subgroups: PFS
Prazo: Up to Approximately 33 Months

PFS is defined as the time from the participant's randomization date to the first occurrence of radiographic progression based on RECIST v1.1 or death from any cause, whichever occurs earlier.

Up to Approximately 33 Months
PD-L1 and c-Met Subgroups: OS
Prazo: Up to Approximately 33 Months

OS is defined as the time from participant's randomization date (Part 2) or first dose date of study treatment (Part 1) to the event of death from any cause.

Up to Approximately 33 Months
PD-L1 and c-Met Subgroups: DOR
Prazo: Up to Approximately 33 Months

DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause, whichever occurs first. DOR is defined for participants with confirmed CR/PR.

Up to Approximately 33 Months
PD-L1 and c-Met Subgroups: DC
Prazo: Up to Approximately 33 Months

DC is defined as best overall response of confirmed CR or confirmed PR, or SD for at least 12 weeks following randomization date based on RECIST v1.1.

Up to Approximately 33 Months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: ABBVIE INC., AbbVie

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

6 de março de 2025

Conclusão Primária (Estimado)

1 de novembro de 2027

Conclusão do estudo (Estimado)

1 de novembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

9 de janeiro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de janeiro de 2025

Primeira postagem (Real)

13 de janeiro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Prazo de Compartilhamento de IPD

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Critérios de acesso de compartilhamento IPD

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever